Dr. Kelly Lyn Warfield began her scientific career as a student intern at the National Institute of Standards and Technologies and National Cancer Institute. Following college at Loyola University, Maryland, Dr. Warfield received her Ph.D. degree in molecular virology from Baylor College of Medicine in Houston, Texas, studying immune responses, pathogenesis and adverse events related to rotavirus vaccination and infection. During a National Research Council postdoctoral fellowship at the United States Army Medical Research Institute of Infectious Diseases, Dr. Warfield became specially trained in BSL-3 and BSL-4 containment laboratories, studying pathogenesis, developing animal models, and developing vaccines and therapeutics for the highly lethal filoviruses.
Dr. Warfield transitioned to the biotechnology industry by co-founding the start-up company Integrated Biotherapeutics, Inc. and was the Vice President of Vaccine Development for 6 years with a focus on development of antivirals and vaccines for Ebola and Marburg viruses. Currently, she is the Senior Director of Antiviral Research and Development at Emergent Virology with responsibility for the preclinical development activities for broad-spectrum antivirals with indications including uncomplicated dengue, influenza and other acute virus infections.